Leading the way to safer medication
 Crosscheck  Recommender

Insulin aspart

Description

The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.

ATC Classification

Code
Title
Category
A10AB05
Insulin aspart
A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AB Insulins and analogues for injection, fast-acting
A10AD05
Insulin aspart
A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting

Trade names

Trade name
Countries

Australia Austria Canada Cyprus France

Australia Austria Canada Cyprus France

Australia Austria Canada Cyprus France

United Kingdom

Trade names (in combination): RYZODEG

Product Monographs

Monograph
Type
Country
NOVORAPID Solution for injection in vial / Cartridge / Pre-filled pen
MPI, EU: SmPC